The SIG-backed video communication software provider priced its shares above the range and will go public later today.

Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.

Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.

The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.

The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.

Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.

The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.

Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.